UK digital pathology provider Source BioScience chooses Sectra to enable seamless pathology collaboration across the NHS. Linköping, Sweden - September 21, 2026 - International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed an agreement with Source BioScience UK Ltd (Source BioScience) in the UK to deliver its service for advanced share and collaborate workflows. As the first Sectra customer in this domain, Source BioScience will now be able to support NHS organisations that need to send pathology cases to external specialists. This lays the foundation for national telepathology networks in the UK, and for improved access to specialist pathologists. The service, Sectra Image Exchange Portal (Sectra IEP), is a cloud-based, vendor-neutral platform for exchanging and collaborating around medical images. It is already used by more than 500 institutions, mainly within radiology. Recently, the service has undergone substantial modernisation which now makes it possible for healthcare providers to benefit from new advanced workflow functionality, for the service to be used by specialties other than radiology and for customers to move beyond image sharing to managing workflows between organisations. "This milestone integration will give the NHS a seamless digital pathway to external specialists, with diagnoses delivered straight back into its own records - reducing turnaround times, easing consultant shortages and tackling reporting backlogs," says Nick Bills, Healthcare Director at Source BioScience. Source BioScience is a UK laboratory services provider specialising in histopathology and genomics. Its pathology business supports more than 85 NHS trusts alongside a network of private healthcare clinics, with histopathology delivered from laboratories in Nottingham, Chichester and Cambridge. NHS pathology services are handling growing case volumes with a limited number of reporting consultants, and increasing subspecialisation means the pathologist best suited to a case is often at another organisation. Sending work to external capacity providers today typically relies on bespoke arrangements between individual laboratories, including the transportation of physical glass slides. This slows reporting times and creates administrative overhead for both the sending and receiving laboratories. With Sectra's service, a case can be created as a job directly from a laboratory's worklist, delegated to a receiving organisation, and the completed report returned to the referring organisation's own records. "IEP is the backbone of image sharing across the NHS. With our modernised platform, we are introducing advanced workflows between healthcare organisations, and extending that trusted national network into pathology. Connecting trusts directly with external specialists like Source BioScience means cases and completed reports move seamlessly across organisational boundaries. It is a step towards an NHS where expertise is always within reach, and where work moves between organisations as easily as it moves within them," says Jane Rendall, Managing Director for Sectra UK and Ireland. The three-year contract was signed in the second quarter of Sectra's 2026/2027 fiscal year. Up to 60,000 cases are expected during the first year, scaling up in subsequent years. Source BioScience Media Contact: Klaudyna Johnstone, Commercial Director, [email protected] For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27 Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10 About Sectra Sectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 23 countries, and distribution partners worldwide. Sales in the 2025/2026 fiscal year totaled SEK 3,542 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra's website.

Source BioScience selects Indica Labs' HALO AP(R) as the digital pathology platform powering the future of NHS outsourcing in the United Kingdom. BY Erica Goodpaster Albuquerque, NM, and Nottingham, September 8, 2026 - Indica Labs, the trusted global leader in AI-powered digital pathology and Source Bioscience, the United Kingdom's leading provider of histopathology services, today announced Source Bioscience's successful expansion of its digital pathology operation powered by HALO AP(R). Since going live at Nottingham headquarters in October 2025, the organization has demonstrated how an interoperable, scanner-agnostic enterprise platform can eliminate one of the greatest barriers to large-scale digital pathology outsourcing while enabling rapid laboratory growth. For NHS trusts evaluating outsourcing partners, interoperability remains one of the greatest obstacles to digital pathology adoption. Differences in scanner hardware, laboratory information management systems (LIMS), and image formats often make it difficult to exchange digital slides and patient data efficiently across organizations. These technical barriers and slow turnaround times, complicate workflows, and limit laboratories' ability to scale digital pathology services. HALO AP(R) addresses these challenges through a scanner-agnostic architecture that supports direct image transfer and automatic file format conversion, enabling referring sites to send digital slides to most scanner manufacturers. Direct LIMS-to-LIMS integration further streamlines the testing pathway by allowing orders, patient information, images, and reports to move seamlessly between organizations. The result is a fully digital workflow that shortens turnaround times by two to three days while improving traceability, compliance, and long-term image retention. As a UKAS-accredited provider with laboratory locations in Nottingham, Chichester, and Cambridge, Source Bioscience delivers comprehensive histopathology services across every subspecialty. The organization supports more than 90 NHS trusts, works with over 280 consultant pathologists, reports more than 350,000 cases annually, and scanned more than one million slides over the past year. Supported by dedicated couriers, laboratory integration, and technical services, Source Bioscience consistently meets or exceeds NHS turnaround time requirements while helping healthcare providers address increasing diagnostic demand. "We are proud to have selected HALO AP(R) as our digital pathology platform," said Dr. Sinduh Menon, Deputy Medical Director for Source BioScience LD Path. "Its robust, scalable, and intuitive environment has enabled us to efficiently manage high-volume workflows while streamlining case review, enhancing collaboration, and providing reliable access to digital pathology data. The exceptional training and ongoing support from the HALO AP(R) team were instrumental in ensuring a smooth implementation and successful adoption across our organization. HALO AP(R) plays an important role in our commitment to innovation and the continued advancement of digital pathology, and we value our partnership with Indica Labs as we continue to expand our digital capabilities." The next phase of Source BioScience's digital transformation is already underway with the rollout of HALO AP(R) at its Chichester laboratory site. Initially supporting private diagnostic services, the site is expected to begin supporting NHS workflows within the coming months, significantly expanding digital reporting capacity across the organization. Additionally, Source BioScience plans to further expand its use of artificial intelligence within HALO AP(R), beginning with Ai-powered quality control and building toward future capabilities supporting clinical trials and AI-assisted pathology workflows. "Large-scale digital pathology depends on interoperability," said Steven Hashagen, CEO of Indica Labs. "Source BioScience has shown how an enterprise platform can remove integration barriers while supporting high-volume diagnostic workflows. We are excited to continue supporting their vision as they expand AI-enabled pathology services across the UK." With continued investment in digital pathology infrastructure, interoperability and scalable enterprise workflows, Source BioScience is positioning itself to become the United Kingdom's premier outsourced digital histopathology partner for both NHS and private healthcare organizations. Regulatory. HALO AP(R) is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP(R) is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP(R) provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR. PRR-MAR-000014v1 About Indica Labs: Indica Labs, the global leader in AI-powered digital pathology, is redefining medicine with pathology platforms supporting life science discovery, translational research, clinical workflows, and companion diagnostic development. HALO platforms integrate image management and quantitative image analysis to deliver standardized, reproducible tissue-based analysis at every stage of the translational journey. About Source BioScience. Source BioScience, comprised of Source LDPath and Source Genomics, provides industry-leading laboratory services in genomics, multiomics and healthcare diagnostics, partnering with biotechnology, pharmaceutical, healthcare and academia. For more information, please visit www.sourcebioscience.com. Indica Labs Media Contact: Source BioScience Media Contact: